Effectiveness and safety of pirfenidone for radiation-induced lung injury in non-small cell lung cancer: a retrospective pilot study
Our findings provide preliminary evidence supporting the clinical benefit and tolerability of pirfenidone for RILI in NSCLC patients. These results warrant further investigation in prospective controlled trials to establish its role in routine clinical practice.
Authors
- Tony He (ORCID: https://orcid.org/0000-0002-5363-7780)
- Benlan Li
- Guojian Liao (ORCID: https://orcid.org/0000-0001-6133-7625)
- Xia Ji (ORCID: https://orcid.org/0000-0001-7597-2769)
- Hong Yang (ORCID: https://orcid.org/0000-0002-6707-8481)
- Shengfa Su (ORCID: https://orcid.org/0000-0002-6429-0081)
- Lili Zhao (ORCID: https://orcid.org/0000-0001-6306-0869)
- Dan Zou
- Fangyang Lu
- Xuzhen Liu (ORCID: https://orcid.org/0009-0008-2365-7079)
- Zhongjun Huang
- Bing Lü (ORCID: https://orcid.org/0000-0001-9385-3931)
- Lingyun Wang (ORCID: https://orcid.org/0000-0002-2522-5439)
- Jie Peng (ORCID: https://orcid.org/0000-0001-8907-701X)
- Yong Hu (ORCID: https://orcid.org/0000-0002-4440-1450)
- Minfang Wang
Institutions
- Guiyang Medical University (CN)
- Wuhan Pulmonary Hospital (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- The First People's Hospital of Guiyang (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1186/s12885-025-14896-1
- Citations
- 1
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Guizhou Medical University
- Wu Jieping Medical Foundation
- Environment Building for Science and Technology Industries